Tired of ads? Enjoy an ad-free experience by signing up.
👩‍🍳 How we use AI at Tech in Asia, thoughtfully and responsibly.
🧔‍♂️ A friendly human may check it before it goes live. More news here

Alphabet-backed Isomorphic Labs raises $5b series C

Isomorphic Labs, a London-based AI drug discovery company backed by Alphabet, announced a US$5 billion series C on November 17. Greenoaks and Sequoia Capital co-led the round.

The funding will support its AI models, biology research, and clinical development infrastructure as it advances drug candidates toward human trials.

Isomorphic Labs was founded in 2021 as a spinout from Google DeepMind, Alphabet’s AI research unit.

Isomorphic previously raised US$2.1 billion in a May 2026 series B. It is also ranked among the most heavily funded startups in AI drug discovery.

Isomorphic said it had positive preclinical results in oncology, immunology, and programs with partners. Its 2024 collaborations with Eli Lilly and Novartis had a combined potential value of nearly US$3 billion.

In January 2026, its clinical trial timeline had been delayed. In the latest announcement, Isomorphic said its first therapeutic programs were still progressing toward trials.

🔗 Source: Isomorphic Labs

Recent Isomorphic Labs developments

Stay ahead in Asia’s tech landscape

You've reached your 2 free content limit for the month. Sign up for free to read the full story.

🏄 For casual readers / 👶 Free

Basic

US$0

Free forever

Get instant access to this article and more every month

0 premium content

Unlimited news briefs

5

5 articles

Ad-free reading experience

Just US$0 per day

⌛Sign up in 20s. No payment details needed.

📖 For learners / 👍 Starter

Lite

US$4.92/month

Billed annually at US$59/year

Get instant access to this article and more every month

4

4 premium content

Unlimited news briefs & articles

Ad-free reading experience

Just US$0.17 per day

Cancel anytime

Our subscriber community includes professionals from these companies: